Medicine Research Studies | Medical News, Treatment Articles


FDA Approves Triple Combination Therapy for Cystic Fibrosis

The Food and Drug Administration (FDA) has approved Trikafta (elexacaftor/tezacaftor/ivacaftor; Vertex) for the treatment of patients aged 12 years and older with cystic fibrosis (CF) who have ≥1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Trikafta is a fixed-dose combination containing elexacaftor 100mg, tezacaftor 50mg, and ivacaftor 75mg that is co-packaged…

CDC Releases Clinical Guidance on E-Cigarette Lung Injury

In an early-release Oct. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, the CDC presents interim guidance to help clinicians assess, evaluate, manage, and follow patients with electronic cigarette, or vaping, product use-associated lung injury.

Fighting a Silent Killer: Identifying Chronic Kidney Disease at Stage 1

The benefits of early diagnosis of chronic kidney disease (CKD) are significant, as patients in whom CKD is diagnosed in the early stages have the chance to make lifestyle changes, learn how to manage their disease, and extend their lives while avoiding or postponing the need for dialysis or transplant.
Next post in Medicine